Tag: ASX: IMC
Immuron prepares for diarrhoea-focused clinical trial as US FDA lifts clinical hold
Immuron, an Australia-based biopharmaceutical company, is slated to move forward with the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) following approval from the US Food and Drug Administration (FDA).
Featured Article
How AI-enabled cloud ERP is redefining growth for manufacturing leaders
Manufacturing leaders are entering a new phase of supply chain transformation, where growth is increasingly determined by how quickly and intelligently organisations can respond to change.
